Quest Diagnostics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DGX and other ETFs, options, and stocks.

About DGX

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. 

CEO
James E. Davis
CEOJames E. Davis
Employees
56,000
Employees56,000
Headquarters
Secaucus, New Jersey
HeadquartersSecaucus, New Jersey
Founded
1967
Founded1967
Employees
56,000
Employees56,000

DGX Key Statistics

Market cap
19.60B
Market cap19.60B
Price-Earnings ratio
21.02
Price-Earnings ratio21.02
Dividend yield
1.76%
Dividend yield1.76%
Average volume
1.04M
Average volume1.04M
High today
$179.79
High today$179.79
Low today
$176.03
Low today$176.03
Open price
$179.19
Open price$179.19
Volume
944.03K
Volume944.03K
52 Week high
$197.55
52 Week high$197.55
52 Week low
$148.70
52 Week low$148.70

Stock Snapshot

The current Quest Diagnostics(DGX) stock price is $176.15, with a market capitalization of 19.6B. The stock trades at a price-to-earnings (P/E) ratio of 21.02 and offers a dividend yield of 1.8%.

As of 2025-12-18, Quest Diagnostics(DGX) stock has fluctuated between $176.03 and $179.79. The current price stands at $176.15, placing the stock +0.1% above today's low and -2.0% off the high.

Quest Diagnostics(DGX) shares are trading with a volume of 944.03K, against a daily average of 1.04M.

In the last year, Quest Diagnostics(DGX) shares hit a 52-week high of $197.55 and a 52-week low of $148.70.

In the last year, Quest Diagnostics(DGX) shares hit a 52-week high of $197.55 and a 52-week low of $148.70.

DGX News

Sherwood News 2d
How health startups are turning blood testing and analysis into a sales funnel

Richard Adams thinks he might be “the most phlebotomized man in America.” Adams, senior vice president of Quest Diagnostics' consumer unit, wears an Oura ring...

How health startups are turning blood testing and analysis into a sales funnel
Simply Wall St 3d
How Investors May Respond To Quest Diagnostics Partnering With Octave On Nationwide MS Activity Testing

On 1 December 2025, Octave Bioscience announced a collaboration with Quest Diagnostics to offer Octave’s Multiple Sclerosis Disease Activity blood test through...

How Investors May Respond To Quest Diagnostics Partnering With Octave On Nationwide MS Activity Testing
Simply Wall St 5d
Quest Diagnostics: Revisiting Valuation After New Multiple Sclerosis Testing Partnership With Octave Bioscience

Quest Diagnostics (DGX) just deepened its neurological testing ambitions through a new collaboration with Octave Bioscience, giving nationwide access to Octave’...

Quest Diagnostics: Revisiting Valuation After New Multiple Sclerosis Testing Partnership With Octave Bioscience

Analyst ratings

55%

of 22 ratings
Buy
40.9%
Hold
54.5%
Sell
4.5%

People also own

Based on the portfolios of people who own DGX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.